1. Home
  2. CRSP vs LMND Comparison

CRSP vs LMND Comparison

Compare CRSP & LMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • LMND
  • Stock Information
  • Founded
  • CRSP 2013
  • LMND 2015
  • Country
  • CRSP Switzerland
  • LMND United States
  • Employees
  • CRSP N/A
  • LMND N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • LMND Property-Casualty Insurers
  • Sector
  • CRSP Health Care
  • LMND Finance
  • Exchange
  • CRSP Nasdaq
  • LMND Nasdaq
  • Market Cap
  • CRSP 3.4B
  • LMND 2.7B
  • IPO Year
  • CRSP 2016
  • LMND 2020
  • Fundamental
  • Price
  • CRSP $36.99
  • LMND $32.50
  • Analyst Decision
  • CRSP Buy
  • LMND Hold
  • Analyst Count
  • CRSP 19
  • LMND 8
  • Target Price
  • CRSP $74.35
  • LMND $35.75
  • AVG Volume (30 Days)
  • CRSP 1.6M
  • LMND 2.0M
  • Earning Date
  • CRSP 05-07-2025
  • LMND 04-29-2025
  • Dividend Yield
  • CRSP N/A
  • LMND N/A
  • EPS Growth
  • CRSP N/A
  • LMND N/A
  • EPS
  • CRSP N/A
  • LMND N/A
  • Revenue
  • CRSP $37,314,000.00
  • LMND $526,500,000.00
  • Revenue This Year
  • CRSP $49.76
  • LMND N/A
  • Revenue Next Year
  • CRSP $257.28
  • LMND $32.26
  • P/E Ratio
  • CRSP N/A
  • LMND N/A
  • Revenue Growth
  • CRSP N/A
  • LMND 22.50
  • 52 Week Low
  • CRSP $36.52
  • LMND $14.03
  • 52 Week High
  • CRSP $68.39
  • LMND $53.85
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 34.31
  • LMND 43.99
  • Support Level
  • CRSP $40.41
  • LMND $33.33
  • Resistance Level
  • CRSP $42.72
  • LMND $37.90
  • Average True Range (ATR)
  • CRSP 1.73
  • LMND 2.52
  • MACD
  • CRSP -0.55
  • LMND -0.18
  • Stochastic Oscillator
  • CRSP 0.80
  • LMND 9.79

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About LMND Lemonade Inc.

Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes. The company is using technology, data, artificial intelligence, contemporary design, and social impact to deliver delightful and affordable insurances. Geographically, it operates in California, Texas, New York, New Jersey, Illinois, Georgia, Washington, Colorado, Pennsylvania, Oregon and others.

Share on Social Networks: